Back from (BTKi) holiday.
作者信息
Brander Danielle M, Sitlinger Andrea
机构信息
Division of Hematologic Malignancies and Cellular Therapy, Duke University, Duke Cancer Institute, Durham, NC.
出版信息
Blood Adv. 2025 Jan 14;9(1):222-223. doi: 10.1182/bloodadvances.2024014309.
Abstract
摘要
相似文献
1
Back from (BTKi) holiday.从（布鲁顿酪氨酸激酶抑制剂）假期归来。
Blood Adv. 2025 Jan 14;9(1):222-223. doi: 10.1182/bloodadvances.2024014309.
2
A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂耐药机制的研究进展。
Int J Mol Sci. 2024 May 11;25(10):5246. doi: 10.3390/ijms25105246.
3
Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.联合抗 CD20 单克隆抗体治疗慢性淋巴细胞白血病对布鲁顿酪氨酸激酶抑制剂治疗的疗效和安全性：一项荟萃分析。
Sci Rep. 2023 Jun 16;13(1):9775. doi: 10.1038/s41598-023-36279-x.
4
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.治疗初治慢性淋巴细胞白血病的治疗方法选择中存在的未解决问题。
J Hematol Oncol. 2023 Jul 8;16(1):72. doi: 10.1186/s13045-023-01469-7.
5
Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China.中国接受 BTK 抑制剂治疗的 B 细胞淋巴增生性疾病患者的真实世界治疗模式、停药和临床结局。
Front Immunol. 2023 Jul 7;14:1184395. doi: 10.3389/fimmu.2023.1184395. eCollection 2023.
6
A prediction model for severe hematological toxicity of BTK inhibitors.BTK 抑制剂致严重血液学毒性预测模型
Ann Hematol. 2023 Oct;102(10):2765-2777. doi: 10.1007/s00277-023-05371-7. Epub 2023 Jul 25.
7
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.在欧洲，布鲁顿酪氨酸激酶抑制剂治疗失败后的复发/难治性套细胞淋巴瘤患者的真实世界经验：SCHOLAR-2 回顾性图表研究。
Br J Haematol. 2023 Aug;202(4):749-759. doi: 10.1111/bjh.18519. Epub 2022 Oct 18.
8
Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.新一代布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中的疗效和安全性：系统评价和荟萃分析。
Ann Hematol. 2024 Jul;103(7):2231-2244. doi: 10.1007/s00277-023-05486-x. Epub 2023 Oct 16.
9
[Immune Reconstitution after BTKi Treatment in Chronic Lymphocytic Leukemia].[慢性淋巴细胞白血病患者接受BTKi治疗后的免疫重建]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Feb;32(1):1-5. doi: 10.19746/j.cnki.issn.1009-2137.2024.01.001.
10
The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.双重 HCK/BTK 抑制剂 KIN-8194 可抑制 BTKi 耐药套细胞淋巴瘤的生长和整合素介导的黏附。
Leukemia. 2024 Jul;38(7):1570-1580. doi: 10.1038/s41375-024-02207-9. Epub 2024 Mar 7.
本文引用的文献
1
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.在E1912研究中接受依鲁替尼治疗的慢性淋巴细胞白血病患者中，根据IGHV突变状态评估的耐受性和长期疾病控制情况
Blood Adv. 2025 Jan 14;9(1):224-228. doi: 10.1182/bloodadvances.2024013474.
2
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.维奈托克联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病：随机 3 期 CLL14 研究 6 年结果。
Blood. 2024 Oct 31;144(18):1924-1935. doi: 10.1182/blood.2024024631.
3
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.在RESONATE-2研究中接受依鲁替尼治疗≥5年的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的特征和临床结局
Cancers (Basel). 2023 Jan 13;15(2):507. doi: 10.3390/cancers15020507.
4
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.RESONATE-2 研究的 8 年随访结果：伊布替尼一线治疗慢性淋巴细胞白血病患者。
Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434.
5
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.新型靶向治疗时代慢性淋巴细胞白血病的预后检测与治疗模式：来自informCLL注册研究的结果
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):174-183.e3. doi: 10.1016/j.clml.2019.10.009. Epub 2019 Oct 21.
6
Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.美国口服靶向治疗时代慢性淋巴细胞白血病的经济负担
J Clin Oncol. 2017 Jan 10;35(2):166-174. doi: 10.1200/JCO.2016.68.2856. Epub 2016 Nov 21.
7
Genomic aberrations and survival in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的基因组畸变与生存情况
N Engl J Med. 2000 Dec 28;343(26):1910-6. doi: 10.1056/NEJM200012283432602.
8
Zotero 插件